Amsterdam-based Leyden Labs plans on developing an intranasal spray based on CR9114.
Leading the round were Casdin Capital and GV (formerly Google Ventures).
Leyden plans on using the most recent funding round to advance its pipeline dedicated to targeting a range of respiratory viruses.
In March, Leyden Labs won €40 (approximately $45) million in Series A financing in a round led by GV.
The company notes that its total fundraising is approximately $200 million.
The most recent funding round “underscores our investors’ belief that Leyden Labs’ platform can generate cornerstone products to combat respiratory diseases,” said Koenraad Wiedhaup, a founder and CEO of Leyden Labs, in a press release. “The ongoing COVID-19 pandemic teaches us we need to expand our arsenal of tools to fight current and future viral outbreaks.”
In 2021, Leyden installed several new executives, including an operations director, director of people and multiple senior directors.
Filed Under: Infectious Disease